PAP System A (with Amalfi) then PAP System B (with CLA11)
DevicePAP System A (with Amalfi) for 7 days followed by PAP System B (with CLA11) for 7 days
NCT Number: NCT06562205
This is a pre-market study for ongoing product development aiming to explore the usability and performance of the study PAP systems.
Trial opening soon.
Get Notified18 year–130 year
All sexes
Interventional
Not applicable
This is an open label, prospective, randomized cross over (or single arm) study for ongoing product development of new accessories for PAP devices. This generic protocol provides a framework methodology for how these ongoing studies will be conducted. This protocol then is used in a number of smaller sub-studies phases, each of which will have their own sub-protocol outlining the exact specifics of the study.
The studies could be run face-to-face or remotely.
Participants who met the inclusion/exclusion criteria will be contacted. Recruitment will be done via emails. Participants will be explained the details of the trial and those who wish to take part will be invited to a selected site for the first study visit.
Visit 1: Participants will provide written informed consent. Participants will be shown the PAP systems and trial them for fit and comfort. Participants may be asked initial questions on their first thoughts on the PAP systems. If the participant and assessor are happy to proceed, the participants will use the loan PAP system for trial.
Visit 2: After trialing the PAP systems, participants will be asked to complete a questionnaire regarding the appeal, comfort, and usability of the PAP system(s). Depending on sub-study protocol, participants will then take the second PAP system home to test.
Visit 3: The participant will return the loan PAP system to the assessor. The participants' questionnaire responses will be reviewed. This concludes the participation in the study.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Additional criteria for remote studies:
Exclusion criteria
PAP System A (with Amalfi) for 7 days followed by PAP System B (with CLA11) for 7 days
PAP System B (with CLA11) for 7 days followed by PAP System A (with Amalfi) for 7 days
Time frame: 6 weeks
Hypothesis: The investigational component/s of the PAP system will be equivalent to the comparison component/s of the PAP system and/or Criterion Score of 6
Subjective usability scores will be collected from participants on each usability item (e.g., comfort, seal, ease of use). Scores will be collected using an 11-point Likert Scale where a score of 10 is considered very favorable, and a score of 0 is very unfavorable
Time frame: 6 weeks
Hypothesis: The investigational component/s of the PAP system will be equivalent to the comparison component/s of the PAP system and/or clinically relevant data
Objective data stored in the CPAP device will be downloaded wirelessly using a computer program (AirView or ResScan, ResMed). An Apnea hypopnea index (AHI) automatically analyzed by the program will be used. Typically, an AHI <5 demonstrates efficacious treatment.
Contact information is provided by the study sponsor or research team.
ResMed
Industry
External Evaluation of PAP Systems: Comparison of PAP Flow Generators Machines, Mask Systems and Tubing
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07724938
Apnea, Dyssomnias
Boston, Massachusetts, United States
View Trial DetailsNCT07716995
Apnea, Dyssomnias
View Trial DetailsNCT07343362
Apnea, Dyssomnias
View Trial DetailsNCT07570953
Apnea, Dyssomnias
Rochester, Minnesota, United States
View Trial Details